These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29106987)

  • 21. Role of B cells in the pathogenesis of systemic sclerosis.
    Sanges S; Guerrier T; Launay D; Lefèvre G; Labalette M; Forestier A; Sobanski V; Corli J; Hauspie C; Jendoubi M; Yakoub-Agha I; Hatron PY; Hachulla E; Dubucquoi S
    Rev Med Interne; 2017 Feb; 38(2):113-124. PubMed ID: 27020403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.
    Pattanaik D; Postlethwaite AE
    Discov Med; 2010 Aug; 10(51):161-7. PubMed ID: 20807477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast.
    Sierra-Sepúlveda A; Esquinca-González A; Benavides-Suárez SA; Sordo-Lima DE; Caballero-Islas AE; Cabral-Castañeda AR; Rodríguez-Reyna TS
    Biomed Res Int; 2019; 2019():4569826. PubMed ID: 30809542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic sclerosis: Is the epithelium a missing piece of the pathogenic puzzle?
    Asano Y; Takahashi T; Saigusa R
    J Dermatol Sci; 2019 May; 94(2):259-265. PubMed ID: 31079997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis.
    Ichihara A; Jinnin M; Ihn H
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):208-210. PubMed ID: 28422002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrosis and immune dysregulation in systemic sclerosis.
    Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
    Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The IL-1 family of cytokines. Do they have a role in scleroderma fibrosis?
    Artlett CM
    Immunol Lett; 2018 Mar; 195():30-37. PubMed ID: 29203183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
    Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S
    Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
    Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
    Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast abnormalities in the pathogenesis of systemic sclerosis.
    Usategui A; del Rey MJ; Pablos JL
    Expert Rev Clin Immunol; 2011 Jul; 7(4):491-8. PubMed ID: 21790292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
    Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
    J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current perspectives on the role of CD8+ T cells in systemic sclerosis.
    Fuschiotti P
    Immunol Lett; 2018 Mar; 195():55-60. PubMed ID: 28987475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
    Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
    Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferons as pathogenic effectors in autoimmunity.
    Baccala R; Kono DH; Theofilopoulos AN
    Immunol Rev; 2005 Apr; 204():9-26. PubMed ID: 15790347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.